PYY hormone may offer effective treatment for type 2 diabetes

NewsGuard 100/100 Score

Researchers at the Norwegian University of Science and Technology (NTNU) and Oxford University have found a hormone that may offer an effective treatment for type 2 diabetes.

The incidence of diabetes, especially type 2 diabetes, has skyrocketed over the last few decades, according to a report from the World Health Organization. The report says that there were 108 million adults with diabetes in 1980, but by 2014, that number had grown to 422 million.

"Many people who are morbidly obese also have type 2 diabetes," says Magnus Kringstad Olsen, a PhD candidate at the Department of Cancer Research and Molecular Medicine at NTNU who was part of the research team.

Gastric bypass surgery is the most effective form of weight loss for the morbidly obese. Patients who undergo the surgery also show great improvements in their diabetes after surgery. Many scientists have wondered why.

Researchers have long believed that the remisssion in type 2 diabetes after bariatic surgery is due to the increased production of GLP-1, an appetite-reducing hormone, says Olsen.

But researchers from NTNU and Oxford discovered that another hormone called PYY has many of the characteristics that cause this effect. The research was done using rats.

The finding offers the possibility that drugs could be used to stimulate the production of the hormone to treat type 2 diabetes.

Source: Norwegian University of Science and Technology

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exercise shown to curb appetite in diabetes and prediabetes patients